UK regulatory consultancy Regulis merges with PharmaLex

Pharmaceutical regulatory consultancy Regulis has merged with specialist services company PharmaLex, in a move that will strengthen the latter’s UK market presence. The sell side was supported throughout the transaction process by Consulting M&A.

Pharmacovigilance, also known as drug safety, is the pharmacological science relating to the collection, detection, assessment, monitoring, and prevention of adverse effects with pharmaceutical products. As the pharmaceutical industry looks to provide solutions to the current Covid-19 pandemic, along with preparing to help combat future emergent viruses, consulting firms able to help pharma firms with the regulatory process are becoming a tempting prospect for merger and acquisition activity.

Founded in 2001, Hertfordshire based consultancy company Regulis specialises in delivering client growth and protecting client assets. Working with companies to speed their products to market and then to protect their patients and the value of their products, the firm’s team of pharmaceutical consultants assist in the European and Global arenas. The team boasts a strong reputation for obtaining rapid regulatory approvals, as well as providing pharmacovigilance and GMP/GDP client solutions.

Ahead of an expected jump in demand for pharmaceutical regulatory support, Regulis has completed a legal merger with PharmaLex Group. The provider of specialised services for the pharma, biotech and medical device industries hopes the move will strengthen its already significant footprint in the UK, while further increasing its market share in the key market.

“PharmaLex and Regulis joining forces offers tremendous potential to our complementary client bases and will contribute further to the successful development of our significant operations and business in the UK”, explained Jon Jeffery, Managing Director of PharmaLex UK.

According to a release from the firms, the two brands are well matched in terms of cultures and values. Considering the strong organic growth of both businesses over recent years, the parties expect that expanding PharmaLex in the UK with the team at Regulis will bring further opportunities for all.

Commenting on the mutual benefits of the deal, Kim Wharton, Managing Director of Regulis, added, “Our services in Regulatory Affairs, Pharmacovigilance and Quality Assurance align perfectly within the PharmaLex portfolio. Becoming part of a larger organisation with an excellent reputation and significant global footprint is an exciting step for Regulis.”

Regulis completed its legal merger with Pharmalex with the support of Consulting M&A throughout the transaction process. Founded in 2019, Consulting M&A is a specialist firm looking to enable owners of consulting and IT services business to grow valuable and sellable businesses.

Wharton added, “We are delighted with the support we had from CM&A. Their knowledge and expertise in corporate finance within the consulting sector helped us through the challenging moments of the process to achieve an outstanding outcome for staff, clients and shareholders.”